ecancer
J

ESMO 2023 Insights: "Alliance A021602 Study - Cabozantinib vs. Placebo for Advanced Neuroendocrine Tumours After Progression on Prior Therapy"

By ecancer FEATURING Jennifer Chan
By ecancer FEATURING Jennifer Chan
143 views
November 14, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:07
Exelixis

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Related Content

AUTOPLAY
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
24:56
Florida Gastroenterologic Society

Neuroendocrine Tumors in the GI Tract

Feat. A. Luthra
06:03
Total Health

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Feat. A. Grothey
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

13:06
Yale Cancer Center

NETs 101 and Overview of Medical Management

Feat. P. Kunz
15:20
Integrity Continuing Education

Sequencing Systemic Treatments for Well-Differentiated NETs

Feat. J. Strosberg
27:34
2023 Johns Hopkins Updates in Gastrointestinal Cancers

Medical Oncology Updates in NETs

Feat. P. Kunz
16:31
Integrity Continuing Education

Debates in NET Treatment: Surgery vs. IR for Liver-Limited Disease

Feat. E. Liu
13:47
Oncology Data Advisor

New Developments in Neuroendocrine Tumor Treatment

Feat. S. Kareff, A. Chauhan
22:31
2023 Johns Hopkins Updates in Gastrointestinal Cancers

Controversies in Management of Neuroendocrine Tumors

Feat. T. Pawlik
19:29
Integrity Continuing Education

Metastatic Grade 2 NET: Case Presentation and Panel Discussion

Feat. A. De Jesus-Acosta, L. Bjork Solnes, J. Strosberg, E. Liu, R. Lidell
11:41
Northwell Health

Neuroendocrine Cancers of the Lung

Feat. N. Seetharamu
12:23
Integrity Continuing Education

2L Therapy for Metastatic NET: Case Presentation and Panel Discussion

Feat. A. De Jesus-Acosta, L. Bjork Solnes, J. Strosberg, E. Liu, R. Lidell
51:13
Yale Cancer Center

The Second Century in the Land of Neuroendocrine Tumors

Feat. J. Yao
37:15
Total Health

Practical Considerations in the Management of Advanced Neuroendocrin…

Feat. J. Del Rivero
09:59
Insights from 2024 ESMO Sarcoma and Rare Cancers Congress

Lurbinectedin + Irinotecan in Pre-Treated Gastroenteropancreatic Neu…

Feat. R. Garcia-Carbonero
07:11
Total Health

ASCO 2022 Non-Colorectal Cancer Updates

Feat. D. Catenacci
10:22
Yale Cancer Center

Imaging Neuroendocrine Tumors

Feat. D. Pucar
05:36
Moffitt Cancer Center

Expert Commentary: Hemicolectomy vs. Appendectomy for Patients With …

Feat. J. Strosberg
27:42
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Fred Hutchinson Cancer Center Updates on Gastroenteropancreatic Neur…

Feat. D. Bing Zhen